AKT1 and intrahepatic cholangiocarcinoma: Indeed, tumor frequency after myr-AKT/α‐catenin expression was drastically lower as compared to injections with constitutively active YAP (YAPS127A)/myr-AKT (leading to intrahepatic cholangiocarcinoma) as well as YAPS127A/β-catenin (leading to hepatoblastoma) [32, 33].